DASL-HiCaP tests darolutamide + ADT + RT in very-high-risk localised prostate cancer, with MFS as the primary endpoint. The result magnitude is still pending. Key question: will the benefit justify 96 weeks of added therapy and toxicity? @niazi_Dr7 @ChrisSweens1 @myESMO #ESMO26 #ProstateCancer